Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEGLUDASE for Intravenous Use 1000 All-case Surveillance
jRCT2031240659Recruiting
- Sponsor
- Ohara Pharmaceutical Co., Ltd.
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of megludase in Methotrexate overdose, sponsored by Ohara Pharmaceutical Co., Ltd. Primary endpoint: Safety (incidence of side effects, etc.). Started Jan 2025; status: recruiting.
02
Drugs
megludase
03
Conditions
Methotrexate overdose
Beyond the preview
Go deeper on jRCT2031240659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240659.